MarketCap
Facebook
X
Telegram
Moderna Financial Ratios 2025-2011 | MRNA
Brief overview of Moderna's market valuation
The comparison uses the five latest available annual observations between 2021 and 2025.
Key multiples at the end of the period are P/S 9.99x (median 4.17x), P/B 2.24x (median 2.65x), P/CF 11.01x (median 11.01x). The multiple basket looks neutral against its history, differing from median levels by roughly 0%.
Returns on assets and capital are represented by ROE -32.6%, ROA -22.9%, ROCE -35.5%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
A shorter cycle, from 126.5 days to -44.1 days, indicates faster release of cash from operations.
What the ratios show
Moderna's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Moderna
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-6.9 | -3.8 | -7.8 | 6.6 | 5.1 | -79.0 | -13.5 | -12.9 | - | - | - | - | - | - | - |
P/S |
10.0 | 4.2 | 5.4 | 2.8 | 3.4 | 73.5 | 115.3 | 36.8 | - | - | - | - | - | - | - |
EPS |
-7.3 | -9.3 | -12.3 | 21.3 | 30.3 | -2.0 | -1.6 | -5.0 | -4.2 | -3.8 | - | - | - | - | - |
EV (Enterprise Value) |
20.5 B | 14.8 B | 38.4 B | 58.4 B | 65.6 B | 61.1 B | 7.12 B | 4.75 B | 312 M | 575 M | - | - | - | - | - |
EBITDA per Share |
-7.36 | -9.79 | -9.48 | 24.8 | 33.6 | -1.92 | -1.56 | -1.18 | - | - | - | - | - | - | - |
EV/EBITDA |
-7.2 | -3.9 | -10.6 | 6.0 | 4.8 | -90.5 | -13.0 | -11.1 | - | - | - | - | - | - | - |
PEG |
0.02 | 0.01 | 0.02 | - | - | 2.01 | 0.42 | 0.63 | - | - | - | - | - | - | - |
P/B |
2.2 | 1.2 | 2.7 | 2.9 | 4.4 | 23.0 | 5.9 | 3.3 | - | - | - | - | - | - | - |
P/CF |
-10.4 | -4.5 | -11.8 | 11.0 | 4.5 | 29.1 | -14.2 | -11.4 | - | - | - | - | - | - | - |
ROE % |
-32.62 | -32.67 | -34.03 | 43.73 | 86.26 | -29.17 | -43.75 | -25.14 | - | - | - | - | - | - | - |
ROA % |
-22.87 | -25.18 | -25.58 | 32.34 | 49.46 | -10.18 | -32.34 | -19.61 | - | - | - | - | - | - | - |
ROCE % |
-35.54 | -36.19 | -30.60 | 49.26 | 94.00 | -29.79 | -37.73 | -23.76 | - | - | - | - | - | - | - |
Current Ratio |
3.3 | 4.4 | 4.0 | 3.8 | 2.3 | 1.5 | 7.9 | 7.0 | - | - | - | - | - | - | - |
DSO |
50.9 | 70.5 | 60.7 | 43.2 | 45.1 | 317.2 | 98.8 | 82.6 | - | - | - | - | - | - | - |
DIO |
56.8 | 39.8 | 44.8 | 80.5 | 103.7 | 1061.4 | - | - | - | - | - | - | - | - | - |
DPO |
151.8 | 115.3 | 39.2 | 26.6 | 22.3 | 580.6 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
107.7 | 110.3 | 105.4 | 123.7 | 148.8 | 1378.6 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-44.1 | -5.0 | 66.3 | 97.2 | 126.5 | 798.0 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Moderna
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.97 | -3.4 | -0.51 | -2.13 | -2.52 | - | 0.03 | -3.33 | -3.07 | - | -9.53 | -3.62 | 0.2 | - | 2.67 | 5.55 | 9.09 | - | 8.27 | 6.93 | 3.05 | - | -0.59 | -0.31 | -0.35 | -0.37 | -0.37 | -0.41 | -0.4 | -1.14 | -1.32 | -1.43 | -1.16 | -0.64 | -1.05 | -1.47 | -1.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.91 | -3.37 | -0.54 | -2.19 | -2.62 | - | -0.05 | -3.45 | -3.22 | - | -4.64 | -4.66 | -0.75 | - | 3.28 | 6.37 | 10.7 | - | 8.98 | 7.79 | 3.2 | - | -0.57 | -0.3 | -0.35 | -0.39 | -0.37 | -0.41 | -0.41 | -0.47 | -1.2 | -1.38 | -1.1 | -0.64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-40.62 | -38.70 | -20.46 | -29.24 | -29.63 | -19.98 | -46.96 | -55.21 | -43.87 | -34.70 | -28.91 | 10.29 | 39.85 | 39.43 | 72.35 | 108.02 | 127.62 | 106.20 | 97.10 | 59.61 | 13.31 | -18.51 | -29.00 | -31.38 | -38.10 | -33.26 | -38.51 | -33.94 | -27.18 | -15.90 | -5.25 | -5.92 | -4.73 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-27.34 | -27.85 | -16.08 | -22.59 | -22.74 | -15.10 | -33.76 | -40.15 | -31.67 | -24.64 | -20.64 | 11.27 | 33.51 | 33.18 | 50.39 | 46.39 | 56.00 | 42.76 | 39.58 | 22.06 | 3.16 | -6.46 | -14.21 | -19.53 | -26.27 | -24.58 | -28.68 | -25.54 | -20.74 | -12.40 | -4.09 | -4.62 | -3.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-43.23 | -41.60 | -23.45 | -32.31 | -32.53 | -22.10 | -37.06 | -47.48 | -37.79 | -27.91 | -21.43 | 7.13 | 42.90 | 44.84 | 79.99 | 119.18 | 138.56 | 113.80 | 104.63 | 64.72 | 13.93 | -19.06 | -30.17 | -32.12 | -39.59 | -46.53 | -45.42 | -39.90 | -34.01 | -27.01 | -9.42 | -6.34 | -5.06 | 7.59 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.6 | 2.8 | 4.3 | 4.6 | 4.8 | 4.4 | 4.1 | 4.0 | 4.3 | 4.0 | 3.2 | 4.4 | 4.6 | 3.8 | 3.2 | - | 2.6 | 2.3 | 1.9 | 1.7 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 | 3.8 | 3.8 | 3.8 | 3.8 | 4.5 | 4.5 | 4.5 | 4.5 | 2.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
27.7 | 131.0 | 48.6 | 36.6 | 184.2 | - | 42.3 | 56.8 | 281.1 | - | 52.3 | 178.4 | 61.2 | - | 36.5 | 30.5 | 47.8 | - | 47.4 | 54.8 | 108.4 | - | 808.5 | 1894.5 | 7963.7 | 34.9 | 28.7 | 36.3 | 47.6 | 30.1 | 25.5 | 37.0 | 37.0 | 5.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
209.0 | 22.8 | 126.1 | 141.1 | 124.2 | - | 72.0 | 275.3 | 236.2 | - | 24.5 | 90.3 | 96.8 | - | 86.2 | 64.2 | 151.8 | - | 101.6 | 69.2 | 127.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
160.9 | 20.4 | 97.4 | 153.7 | 319.9 | - | 57.9 | 183.3 | 334.1 | - | 16.4 | 43.6 | 50.5 | - | 13.7 | 6.6 | 22.5 | - | 10.4 | 5.2 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 174.7 | 177.7 | 308.4 | - | 114.3 | 332.1 | 517.3 | - | 76.8 | 268.7 | 158.1 | - | 122.7 | 94.6 | 199.5 | - | 149.0 | 124.0 | 236.3 | - | 808.5 | 1894.5 | 7963.7 | 34.9 | 28.7 | 36.3 | 47.6 | 30.1 | 25.5 | 37.0 | 37.0 | 5.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 77.2 | 24.0 | -11.5 | - | 56.4 | 148.8 | 183.2 | - | 60.4 | 225.1 | 107.6 | - | 109.0 | 88.1 | 177.0 | - | 138.7 | 118.8 | 230.1 | - | 808.5 | 1894.5 | 7963.7 | 34.9 | 28.7 | 36.3 | 47.6 | 30.1 | 25.5 | 37.0 | 37.0 | 5.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Moderna, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
